PET分期对局部晚期非小细胞肺癌总生存和无进展生存的影响
PROCLAIM研究纳入598例IIIA/B期非鳞非小细胞肺癌患者,比较基线PET分期与否对生存的影响。82.1%患者行PET分期,PET组中位总生存27.2个月对20.8个月(HR=0.81,p=0.130),中位无进展生存11.3个月对9.2个月(HR=0.73,p=0.012)。结论提示PET分期因分期迁移可能改善生存,非治疗因素也可影响结局。
要点
- 基线PET分期与显著改善的无进展生存相关(HR=0.73,p=0.012)。
- PET组总生存数值更长但未达统计学显著(HR=0.81,p=0.130)。
- PET分期带来的分期迁移可能影响生存结局的解读。
核心结论
- PET分期组较常规分期组无进展生存显著改善,总生存数值延长但未达统计学显著。
- 生存差异幅度提示分期迁移等非治疗因素可能影响结局。
研究设计与样本
- PROCLAIM研究为随机对照试验,纳入598例IIIA/B期非鳞非小细胞肺癌患者(意向治疗人群)。
- 患者随机接受培美曲塞联合顺铂同步胸部放疗3周期后培美曲塞巩固4周期,或依托泊苷联合顺铂同步胸部放疗2周期后铂类双药巩固至多2周期。
- 基线PET扫描(是/否)为分层因素之一,在意向治疗人群中按PET是/否进行总生存和无进展生存的亚组分析。
主要发现
- 598例中491例(82.1%)行基线PET分期。
- PET组对非PET组中位总生存为27.2个月对20.8个月(HR=0.81,p=0.130)。
- PET组对非PET组中位无进展生存为11.3个月对9.2个月(HR=0.73,p=0.012)。
临床怎么用
- 局部晚期非小细胞肺癌分期评估中可考虑PET以优化分期。
- 解读生存结局时需考虑PET分期导致的分期迁移对研究结果的影响。
局限性
- 原文未明确报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We investigated the potential impact of stage migration because of positron-emission tomography (PET) scan staging on survival in the locally advanced (stage IIIA/B) NSCLC setting. METHODS: In PROCLAIM, 598 patients with stage IIIA/B nonsquamous NSCLC (intent-to-treat population) were randomized to either pemetrexed plus cisplatin and concurrent thoracic radiotherapy for 3 cycles followed by 4 cycles of pemetrexed consolidation or etoposide plus cisplatin and concurrent thoracic radiotherapy for 2 cycles followed by a consolidation platinum-based doublet regimen for up to 2 cycles. Baseline PET scan (PET Yes versus No) was one of the stratification factors. Subgroup analyses (PET Yes versus No) of overall survival (OS) and progression-free survival (PFS) were conducted on the intent-to-treat population regardless of treatment, as the study did not show superior efficacy for either arm. RESULTS: Majority (491 of 598; 82.1%) of patients had a baseline PET scan staging performed. A longer median OS (PET Yes versus No: 27.2 versus 20.8; hazard ratio = 0.81, p = 0.130) and an improved median PFS (PET Yes versus No: 11.3 versus 9.2; hazard ratio = 0.73, p = 0.012) were observed for patients with PET scans compared to those with conventional staging in both treatment arms. CONCLUSIONS: Both a significantly improved PFS and a numerically longer OS in the PET Yes subgroup, compared to patients with conventional staging, are consistent with improved survival due to stage migration. The magnitude of differences in OS and PFS based on PET scan is a reminder of the potential for factors other than the therapeutic intervention to affect outcomes.
引用
- Vokes EE, Govindan R, Iscoe N, et al. The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. J Thorac Oncol. 2018. PMID: 29733908. doi:10.1016/j.jtho.2018.04.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。